Navigation Links
AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
Date:11/22/2011

IRVINE, Calif., Nov. 22, 2011 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced the recent presentation by Diana Shih, Ph.D., Associate Professor of Medicine, Division of Cardiology at the David Geffen School of Medicine at UCLA, at the 2011 American Heart Association (AHA) Scientific Sessions in Orlando, Florida.  Dr. Shih's presentation included information on research sponsored by the Company which demonstrated that dietary supplementation of AHRO-001 resulted in a 95% reduction in arterial plaque formation at the innominate artery when compared to the control group.

The study results also revealed significant reduction in plasma cholesterol and dietary cholesterol absorption in the test subjects that received HDCA. HDCA supplementation also improved HDL function as measured by cholesterol efflux assay. These factors indicate multiple methods of action for an anti-atherogenic effect, suggesting a clear potential for new anti-atherosclerotic therapy.

"We are extremely pleased with the results of the UCLA study and want to thank Dr. Shih for all of her efforts on this presentation," said Thomas W. Gardner, CEO of AtheroNova. "The data from this study confirms and enhances our initial research and understanding of the compounds. As a result, we are moving forward with the preparation of an Investigative New Drug (IND) application with the Food and Drug Administration (FDA) for our atherosclerotic plaque regression compounds, in addition to, preparations for entry into Phase I human trials during 2012."

"Presenting such positive data to an audience of industry peers at AHA validates the potential of AtheroNova's compounds," Gardner concluded. 

Dr. Shih's presentation can be viewed on the American Heart Association's website at www.scientificsessions.org'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
2. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
3. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
4. SRI International Awarded Two National Cancer Institute Preclinical Development Service Contracts
5. Dr. Ken Kaitin, Tufts CSDD, Keynotes Preclinical Conference
6. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
7. Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
8. Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR
9. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
10. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
11. QPS Expands Into Toxicology Services With Acquisition of the Preclinical Unit of DCB Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 ... has announced the addition of the "Global ... their offering. The Global Biosimilars Market, ... of the rapidly growing biosimilars market. With the ... striving to minimize costs, biosimilars are being viewed ...
(Date:7/29/2015)... July 29, 2015  Therapath Neuropathology ( www.Therapath.com ... partnerships with VA and Military Medical centers both ... Density (ENFD) and Sweat Gland Nerve Fiber Density ... ( https://therapath.com/skin ). Demonstration of ... (ENFD) on punch skin biopsy is a highly ...
(Date:7/29/2015)... ... 29, 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers ... drug/device combinations. The current system received a score of 0 (range -10 to +10) ... (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and ...
(Date:7/29/2015)... Francisco, CA (PRWEB) , ... July 29, 2015 , ... ... in the morning is quite normal. Although there are a considerable number of terms ... well understood that this post-sleep material is a mixture of mucus, blood cells, skin ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Neuropathology services for VA and Military health systems 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4
... PARSIPPANY, N.J., Oct. 2 Pacira Pharmaceuticals, Inc.,an ... of a key senior executive to the company,s ... Vice President of Medical Education and,Scientific Affairs. Dr. ... held several senior management positions since 2001, most ...
... Matthew B. Wiener, PharmD, Chief,Executive Officer of Pharmatech, ... from the Colorado Cancer Coalition. The award is,being ... the Just-In-Time (JIT),enrollment methodology for cancer clinical trials. ... of October 6th, at the St. Mary,s Cancer ...
... of ... plasma-based product in China, TAIAN CITY, China, Oct. ... ("China Biologic" or the,"Company"), one of the leading plasma-based pharmaceutical ... on September 26,2008, the Company has agreed to acquire a ...
Cached Biology Technology:Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team 2Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition 2China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 2China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 3China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 4China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 5
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/23/2015)... , July 23, 2015 Research and ... of the "Global Outlook of the Biometrics ... The global biometrics market is ... and commercial applications owing to the uptake of ... a transformation that enhances the growth of biometrics ...
(Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... Following an agreement between ESA, Krunichev Space Centre and ... and a secondary payload, the technology demonstrator Proba-2 satellite, ... new November launch date follows a rescheduling of the ... Moisture and Ocean Salinity (SMOS) satellite and the secondary ...
... heat shock protein 90 gets steroid receptors into shape ... to targeted therapies for hormone-driven cancers, such as breast ... of Georgia researchers say. "We are trying to ... conformation so they work," says Dr. Ahmed Chadli, biochemist ...
... In the fruit fly,s developing brain, stem cells called ... cell that has a different fate. But neuroblast growth can ... Researchers at Duke-NUS Graduate Medical School in Singapore ... a counterpart in mammals, that can apparently prevent brain tumors ...
Cached Biology News:SMOS and Proba-2 launch rescheduled for November 2Targeting helpers of heat shock proteins could help treat cancer, cardiovascular disease 2Tumor suppressor gene in flies may provide insights for human brain tumors 2
The Holten mini vertical flow workbench provides a particle-free environment for sample protection against airborne contaminants....
...
... combine high durability and capacity with ... use. The patented triple-counterbalanced heavy-duty mechanism ... run at high speed with heavy, ... range is delivered with tight uniformity ...
The 891 45° Fixed Angle Rotor is designed to provide aerosol containment and can be removed from a centrifuge (seal entact) and opened under an environmental hood....
Biology Products: